Recombinant trivalent influenza vaccine (Flublok®): A review of its use in the prevention of seasonal influenza in adults

Drugs

Volumn 73, Issue 12, 2013, Pages 1357-1366

  Yang, Lily P H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTIGENICITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EGG ALLERGY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HLA MATCHING; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INFLUENZA VACCINATION; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SKIN INDURATION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEASONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINATION; YOUNG ADULT;

EID: 84883223706     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0103-6     Document Type: Article

References (38)

1. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 [published errata appear in MMWR Recomm Rep 2010;59(31):993 and 2010;59(35):1147]. MMWR Recomm Rep. 2010;59(RR-8):1-62.
2. Hogan TJ. Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies. Pharmacoeconomics. 2012;30(5):355-71.
3. Newall AT, Kelly H, Harsley S, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics. 2009;27(6):439-50.
4. de Waure C, Veneziano MA, Cadeddu C, et al. Economic value of influenza vaccination. Hum Vaccin Immunother. 2012;8(1):119-29.
5. Rogers KC, Wallace JP, Foster SL, et al. Annual influenza vaccination: offering protection beyond infection. South Med J. 2012;105(7):379-86.
6. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2012;61(32):613-8.
7. Clements KM, Chancellor J, Nichol K, et al. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011;14(6):800-11.
8. Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev Vaccines. 2011;10(7):1063-81.
9. Cox MM. Recombinant protein vaccines produced in insect cells. Vaccine. 2012;30(10):1759-66.
10. Protein Sciences Corporation. Flublok (influenza vaccine) sterile solution for intramuscular injection: US prescribing information; 12 Dec 2012. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM336020.pdf (Accessed 27 Mar 2013).
11. US FDA Centers for Disease Control and Prevention. CDC advisory committee recommends an influenza vaccine option for persons with egg allergy; 20 Jun 2013. http://www.cdc.gov/media/releases/2013/a0620-FluBlok.html (Accessed 1 Jul 2013).
12. Cox MMJ, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol. 2011;107(Suppl):S31-41.
13. Post PL. Safety testing and use of insect cells for recombinant protein production. PDA J Pharm Sci Technol. 2010;64(5):396-418.
14. Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995;171(6):1595-9.
15. Treanor JJ, Betts RF, Smith GE, et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis. 1996;173(6):1467-70.
16. Lakey DL, Treanor JJ, Betts RF, et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis. 1996;174(4):838-41.
17. Powers DC, McElhaney JE, Florendo OA Jr, et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J Infect Dis. 1997;175(2):342-51.
18. Huber VC, McCullers JA. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther. 2008;10(1):75-85.
19. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007;297(14):1577-82.
20. Treanor JJ, Schiff GM, Couch RB, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis. 2006;193(9):1223-8.
21. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29(44):7733-9.
22. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011;29(12):2272-8.
23. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old. Vaccine. 2009;28(2):379-85.
24. Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR MorbMortal Wkly Rep. 2006;55(29):800]. MMWR Recomm Rep. 2006;55(RR-10):1-42.
25. Nolletti C, Schrager L. US FDA clinical review (Flublok); 15 Jan 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM341947.pdf (Accessed 28 Mar 2013).
26. Fritz T. US FDA summary basis for regulatory action (Flublok); 16 Jun 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM338898.pdf (Accessed 28 Mar 2013).
27. Novartis Vaccines and Diagnostics, Inc. Flucelvax (influenza virus vaccine) suspension for intramuscular injection: US prescribing information; 2012. http://www.novartisvaccinesdirect.com/pdf/Flucelvax-PI.pdf (Accessed 14 Jun 2013).
28. European Medicines Agency. Questions and answers on the review of Preflucel and associated names (influenza vaccine, purified antigen); 19 Jul 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Preflucel/WC500130157.pdf (Accessed 30 Apr 2013).
29. Cox MMJ, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009;37(3):182-9.
30. Cox MMJ, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses. 2008;2(6):211-9.
31. Wang K, Holtz KM, Anderson K, et al. Expression and purification of an influenza hemagglutinin: one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2006;24(12):2176-85.
32. MedImmune, LLC. FluMist Quadrivalent (live influenza vaccine) intranasal spray: US prescribing information; Dec 2012. http://www.medimmune.com/docs/ default-source/default-document-library/product-and-patient-information-for- flumist-quadrivalent.pdf?sfvrsn=0 (Accessed 14 Jun 2013).
33. GlaxoSmithKline. Fluarix Quadrivalent (influenza virus vaccine) suspension for intramuscular injection: US prescribing information; Dec 2012. https://www.gsksource.com/gskprm/htdocs/documents/FLUARIX-QUADRIVALENT.PDF (Accessed 14 Jun 2013).
34. Sanofi Pasteur Inc. Fluzone Quadrivalent (influenza virus vaccine) suspension for intramuscular injection: US prescribing information; Jun 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM356094.pdf (Accessed 1 Jul 2013).
35. Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol. 2009;333:227-41.
36. Safdar A, Rodriguez MA, Fayad LE, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006;194(10):1394-7.
37. King JC Jr, Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine. 2009;27(47):6589-94.
38. U. S. Department of Health and Human Services Food and Drug Administration Center for Bologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines; May 2007. http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm091990.pdf (Accessed 17 Apr 2013).